Cardiovasculaire Geneeskunde.nl

NOACs RWE

Overzicht van studies naar ervaringen met non-VKA orale anticoagulantia (NOACs) bij patiënten met atriumfibrilleren in de dagelijkse klinische praktijk (‘real world evidence’). We zullen dit overzicht wanneer relevant blijven aanvullen.

Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation

Själander S, Sjögren V, Renlund H et al.,

Aug. 22, 2018

Själander S, Sjögren V, Renlund H et al., Thromb Res. 2018 May 17;167:113-118

Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World" in Patients With Atrial Fibrillation

Esteve-Pastor MA, Rivera-Caravaca JM, Roldán V et al.

Aug. 22, 2018

Esteve-Pastor MA, Rivera-Caravaca JM, Roldán V et al., Am J Cardiol. 2018 Jun 2

Effectiveness and Safety of Rivaroxaban Versus Warfarin in Nonvalvular Atrial fibrillation Patients with a Non-Sex-Related CHA2DS2-VASc Score of 1

Coleman CI, Turpie AGG, Bunz TJ et al., Eur Heart J Cardiovasc Pharmacother. 2018

July 31, 2018

Coleman CI, Turpie AGG, Bunz TJ et al., Eur Heart J Cardiovasc Pharmacother. 2018

Global Prospective Safety Analysis of Rivaroxaban

Kirchhof P, Radaideh G, Kim Y-H et al., J Am Coll Cardiol 2018;: 72: 2 DOI: 10.1016/j.jacc.2018.04.058

July 9, 2018

Kirchhof P, Radaideh G, Kim Y-H et al., J Am Coll Cardiol 2018; 72: 2 DOI: 10.1016/j.jacc.2018.04.058

Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation

Andersson NW, Svanström H, Lund M et al., Int J Cardiol. 2018

July 3, 2018

Andersson NW, Svanström H, Lund M et al., Int J Cardiol. 2018

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation

Martinez BK, Sood NA, Bunz TJ et al. J Am Heart Assoc. 2018

Apr. 23, 2018

Martinez BK, Sood NA, Bunz TJ et al. J Am Heart Assoc. 2018

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation

Shah S, Norby FL, Datta YH et al., Blood advances 2018

Feb. 4, 2018

Shah S, Norby FL, Datta YH et al., Blood advances 2018

Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach

Li X, Keshishian A, Hamilton M et al., PLoS ONE 2018

Jan. 30, 2018

Li X, Keshishian A, Hamilton M et al., PLoS ONE 2018

Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation

Hohnloser SH, Basic E, Hohmann C et al., Thromb Haemost. 2018

Jan. 22, 2018

Hohnloser SH, Basic E, Hohmann C et al., Thromb Haemost. 2018

Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany

Collings S-L, Lefevre C, Johnson ME et al., PLoS ONE 2017

Jan. 8, 2018

Collings S-L, Lefevre C, Johnson ME et al., PLoS ONE 2017

Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients 80+ Years-of-Age with Nonvalvular Atrial Fibrillation

Coleman CI, Weeda ER, Nguyen E et al., Eur Heart J Qual Care Clin Outcomes. 2017

Dec. 7, 2017

Coleman CI, Weeda ER, Nguyen E et al., Eur Heart J Qual Care Clin Outcomes. 2017

Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation

Yao X, Tangri N, Gersh BJ et al., J Am Coll Cardiol. 2017

Dec. 4, 2017

Yao X, Tangri N, Gersh BJ et al., J Am Coll Cardiol. 2017